2020
Neoantigen-based EpiGVAX vaccine initiates antitumor immunity in colorectal cancer
Kim VM, Pan X, Soares KC, Azad NS, Ahuja N, Gamper CJ, Blair AB, Muth S, Ding D, Ladle BH, Zheng L. Neoantigen-based EpiGVAX vaccine initiates antitumor immunity in colorectal cancer. JCI Insight 2020, 5: e136368. PMID: 32376802, PMCID: PMC7253020, DOI: 10.1172/jci.insight.136368.Peer-Reviewed Original ResearchConceptsMetastatic colorectal cancerColorectal cancerDNA methyltransferase inhibitorAntitumor efficacyAntigen-specific antitumor immune responsesAntitumor T-cell responsesCancer testis antigen expressionAntitumor immune responseT cell responsesAntitumor immunityCancer vaccinesSurvival outcomesCombination therapyAntigen expressionImmune responseMurine modelCTA expressionCell responsesNeoantigensImproved efficacyTumor cellsVaccineEfficacyGVAXMethyltransferase inhibitor
2014
Meta-analysis of randomized trials to study the impact of prednisone on toxicities and survival in metastatic castration-resistant prostate cancer.
Naik G, Morgan C, Galsky M, Oh W, Sonpavde G. Meta-analysis of randomized trials to study the impact of prednisone on toxicities and survival in metastatic castration-resistant prostate cancer. Journal Of Clinical Oncology 2014, 32: 28-28. DOI: 10.1200/jco.2014.32.4_suppl.28.Peer-Reviewed Original ResearchMetastatic castration-resistant prostate cancerMeta-analysis of randomized trialsCastration-resistant prostate cancerOverall survivalDaily oral prednisoneNon-PE groupRandomized trialsOral prednisoneProstate cancerMeta-analysisSevere toxicityImpact of prednisoneToxicity grade 3Discontinued therapyEstramustine phosphateOS analysisGrade 3P. CONCLUSIONSPrednisonePreferred Reporting ItemsAnalysis of toxicityTherapyPatientsGVAXSystematic review
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply